MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Atara Biotherapeutics Total Liabilities 2011-2026 | ATRA
Annual Total Liabilities Atara Biotherapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 206 M | 265 M | 250 M | 189 M | 126 M | 52.2 M | 53 M | 39.9 M | 10.2 M | 9.88 M | 2.94 M | 62.8 M | 8.02 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 265 M | 2.94 M | 98 M |
Quarterly Total Liabilities Atara Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 66.8 M | 71.9 M | 117 M | 206 M | 233 M | 228 M | 264 M | 265 M | 240 M | 239 M | 237 M | 250 M | 181 M | 179 M | 173 M | 189 M | 140 M | 125 M | 131 M | 126 M | 126 M | 126 M | 126 M | 52.2 M | 52.2 M | 52.2 M | 52.2 M | 53 M | 53 M | 53 M | 53 M | 39.9 M | 39.9 M | 39.9 M | 39.9 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 9.88 M | 9.88 M | 9.88 M | 9.88 M | 2.94 M | 2.94 M | 2.94 M | 2.94 M | 1.75 M | 1.75 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 265 M | 1.75 M | 96.2 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
ADMA Biologics
ADMA
|
147 M | $ 16.49 | -0.3 % | $ 3.93 B | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.59 | -1.1 % | $ 1.07 B |  Canada |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
705 M | $ 20.5 | 3.22 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.81 | -1.57 % | $ 4.42 M | China |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
855 M | $ 75.14 | -1.82 % | $ 1.45 B | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
355 M | $ 1.57 | -3.68 % | $ 401 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Athersys
ATHX
|
28.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
59.5 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 163.09 | -0.61 % | $ 8.11 B | USA |
 |
Champions Oncology
CSBR
|
28.6 M | $ 6.0 | - | $ 82 M | USA |
 |
BridgeBio Pharma
BBIO
|
3.01 B | $ 65.5 | -1.57 % | $ 12.5 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
9.6 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
25.4 M | $ 2.84 | 1.07 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.51 B | $ 60.3 | -0.22 % | $ 11.6 B | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.34 | -0.48 % | $ 1.36 B | Britain |
 |
Cabaletta Bio
CABA
|
17.5 M | $ 3.37 | -1.75 % | $ 3.94 M | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
387 M | $ 3.04 | -5.0 % | $ 1.09 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
8.23 M | $ 0.59 | - | $ 549 K | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 25.56 | 0.22 % | $ 684 M | USA |